Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Group 1 - Adverum Biotechnologies is a clinical-stage company focused on gene therapy for prevalent ocular diseases, aiming to establish a new standard of care to restore vision and prevent blindness [2] - The company is developing a novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), intended as a one-time intravitreal injection for patients with neovascular or wet age-related macular degeneration [2] - Adverum's proprietary intravitreal platform is designed to provide durable, single-administration therapies, reducing the need for frequent ocular injections [2] Group 2 - Adverum will present at several upcoming investor conferences, including the 2024 RBC Global Healthcare Conference on May 14, 2024, the BofA Securities 2024 Health Care Conference on May 16, 2024, and the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024 [1] - The company will provide on-demand webcasts of the panel discussions, accessible on its website, with replays available for at least 30 days following the presentations [1]